Results 11 to 20 of about 5,969 (169)

Non-Pulmonary Mechanisms of Action of Ambroxol in In Vivo Experimental Models: a Systematic Review. [PDF]

Fundam Clin Pharmacol
ABSTRACT Background Repositioning offers a cost‐effective approach to discovering new therapeutic applications for existing medications. Ambroxol, primarily used as a mucolytic for respiratory diseases, has demonstrated anti‐inflammatory, analgesic, and antioxidant properties, suggesting potential benefits in non‐pulmonary conditions.
Mesquita MJTAM, da Cruz ACSN, de Abreu Lima R, Tenório-Meireles J, Farias AJN, Santos IN, Frota G, de Moura Carvalho TGP, Carvalho RAF, Meireles-Teixeira JA, Prazeres T, Carvalho RC, do Socorro de Sousa Cartágenes M, Garcia JBS.   +13 more
europepmc   +2 more sources

The Race to Salvage Glucocerebrosidase: Understanding Small-Molecule Therapies for GBA1-Associated Parkinsonism. [PDF]

Mov Disord
Variants in GBA1, the gene encoding the lysosomal enzyme glucocerebrosidase, cause Gaucher disease and confer an increased risk for parkinsonism. Strategies using small molecules can improve the function of glucocerebrosidase in lysosomes. A clear understanding of the mechanism‐of‐action of these compounds will facilitate development of GBA1‐modulating
Henderson MJ, Chen TC, Glasstetter LM, Chen Y, Marugan JJ, Sidransky E.   +5 more
europepmc   +2 more sources

Ambroxol: A potential therapeutics against neurodegeneration

Health Sciences Review, 2023
Ambroxol hydrochloride is a pharmacological chaperone approved by FDA as an expectorant. Currently, it is used as an antitussive and anti-asthmatic agent.
Prajwal Dhanve, Punita Aggarwal, Sourabh Choure, Devendra K. Dhaked, Sugato Banerjee   +4 more
doaj   +1 more source

Rational mucolytic therapy with ambroxol: controversial and indisputable. A review

Consilium Medicum, 2023
Many years of experience in the use of ambroxol is based on its ability to regulate the basic mechanisms of physiological production and transport of bronchial mucus.
Sergey L. Babak, Marina V. Gorbunova, Andrey G. Malyavin   +2 more
doaj   +1 more source

Ambroxol therapy for Parkinson’s disease: Systematic literature review [PDF]

Romanian Journal of Neurology, 2023
Parkinson’s disease (PD) is the second most common neurodegenerative disease. The accumulation of α-synuclein protein in the basal ganglia is the underlying pathogenesis of PD. Genetic abnormalities are one of the predisposing factors for PD.
Virgi Mayang Maharani, Ken Wirastuti, Meyvita Silviana, Naili Sofi Riasari   +3 more
doaj   +1 more source

PERBANDINGAN MUTU FISIK TABLET AMBROXOL MEREK DAGANG X DANTABLETMBROXOL GENERIK

Jurnal Farmasi Sains dan Praktis, 2018
Ambroxol adalah salah satu obat yang masuk kedalam golongan mukolitik. Dimana tujuan dari penelitian ini adalah mengetahui perbandingan mutu fisik tablet Ambroxol merek dagang dan tablet Ambroxol generik.
oktavia friski, Prasojo Pribadi, Imron Hidayat   +2 more
doaj   +1 more source

Beneficial effects of ambroxol hydrochloride on pentylenetetrazol-induced convulsion model in rats

Medicine Science, 2020
In present experimental study, we purposed to research if ambroxol would have beneficial acute effects on PTZ-induced convulsions by EEG records. 48 rats were randomly divided into two groups; group A for EEG recordings and B for behavioral evaluations ...
Eda Sunnetci, Volkan Solmaz, Halil Ugur Hatipoglu, Oytun Erbas   +3 more
doaj   +1 more source

Human peritoneal mesothelial cell death induced by high-glucose hypertonic solution involves Ca2+ and Na+ ions and oxidative stress with the participation of PKC/NOX2 and PI3K/Akt pathways [PDF]

, 2017
Indexación: Web of Science; Scopus.Chronic peritoneal dialysis (PD) therapy is equally efficient as hemodialysis while providing greater patient comfort and mobility. Therefore, PD is the treatment of choice for several types of renal patients. During PD,
Alejandro Pacheco, Alejandro Vallejos, Cesar Echeverria, Erico Segovia, Felipe Simon, Felipe Simon, Maria E. Sanhueza, Miriam Alvo, Pablo Tapia, Ricardo Armisen, Ricardo Armisen, Rubén Torres, Rubén Torres, Sebastian Gatica   +13 more
core   +2 more sources

Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons [PDF]

, 2018
Glucocerebrosidase (GBA1) mutations are the major genetic risk factor for Parkinson's Disease (PD). The pathogenic mechanism is still unclear, but alterations in lysosomal-autophagy processes are implicated due to reduction of mutated glucocerebrosidase (
Gegg, ME, Magalhaes, J, Migdalska-Richards, A, Schapira, AH   +3 more
core   +1 more source

Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models [PDF]

, 2016
GBA gene mutations are the greatest cause of Parkinson disease (PD). GBA encodes the lysosomal enzyme glucocerebrosidase (GCase) but the mechanisms by which loss of GCase contributes to PD remain unclear.
Beavan, M, Chau, K-Y, Gegg, ME, Sanchez-Martinez, A, Schapira, AHV, Whitworth, AJ   +5 more
core   +1 more source